Skip to main content
SpringerLink
Log in

Podophyllotoxin derivative VP 16-213

  • General Review
  • VP 16-213
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

VP 16-213, a derivative of podophyllotoxin, is currently entering phase-III studies. Its mode of action is incompletely understood, but differs markedly from that of its parent compound. The greatest lethal damage is experienced by cells in the late S and G2 phases. In the L1210 system the drug shows marked schedule dependency: prolonged administration may be more effective than single bolus administration.

As a single agent, VP 16-213 is the most active compound yet tested against small-cell bronchial carcinoma. It may also prove to be a useful agent in patients with other types of lung tumour, testicular teratomas, and some types of leukaemia. No long-term or cumulative toxicity has been reported. Most side effects are predictable and reproducible.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ahmann, D. L., Bisei, H. F., Eagan, R. T., Edmonson, J. H., Hahn, R. G., O'Connell, M. J., Frytak, S.: Phase II evaluation of V.P. 16-213 (NSC 141540) and cytembena (NSC 104801) in patients with advanced breast cancer. Cancer Treat. Rep. 60, 633 (1976)

    Google Scholar 

  2. Allen, L. M., Creavan, P. J.: Comparison of the human pharmacokinetics of V. M. 26 and V. P. 16-213, two antineoplastic epipodophyllotoxin glucopyranoside derivatives. Eur. J. Cancer 11, 697 (1975)

    Google Scholar 

  3. Allen, L. M., Shirley, M.: Mechanism of cellular transport of two epipodophyllotoxin glucopyranoside derivatives, V.M. 26 and V.P. 16. Proc. Am. Assoc. Cancer Res. 18, 22 (1977)

    Google Scholar 

  4. Allen, L. M., Marks, C., Creaven, J.: 4′-Demethyl-epipodophyllic acid-9-(4,6-0-ethylidene-β-d-glucopyranoside). The major urinary metabolite of V.P. 16-213 in man. Proc. Am. Assoc. Cancer Res. 17, 6 (1976)

    Google Scholar 

  5. Beveridge, T., Kalberer, F., Nuesch, E.: Bioavailability study with 3H-V.P. 16-213 (Internal report). Basle: Sandoz 1974

    Google Scholar 

  6. Beveridge, T., Kalberer, F., Nuesch, E.: Bioavailability study with 3H-V.P. 16-213 in man (Internal report). Basle: Sandoz 1976

    Google Scholar 

  7. Brunner, K. W., Sonntag, R. W., Ryssel, H. J., Cavalli, F.: Comparison of the biologic activity of V.P. 16-213 given IV and orally in capsules or drink ampoules. Cancer Treat. Rep. 60, 1377 (1976)

    Google Scholar 

  8. Cattan, A., Pourny, C., Carpentier, Y., Cattan, E., Barouh, M.: Antimetastasis effect of two derivatives of epiopodophyllotoxin in mice. Eur. J. Cancer 12, 797 (1976)

    Google Scholar 

  9. Cavalli, F., Sonntag, R., Brunner, K. W.: Epipodophyllotoxin V.P. 16-213 in acute non-lymphoblastic leukaemia. (Letter) Br. Med. J. 1975 1, 227

    Google Scholar 

  10. Cavalli, F., Sonntag, R. W., Jungi, F., Senn, H. J., Brunner, K. W.: V.P. 16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules. Cancer Treat. Rep. 62, 473 (1978)

    Google Scholar 

  11. Cecil, J. W., Quagliana, J. M., Coltman, C. A., Al-Sarraf, M., Thigpen, T., Groppe, C. W.: Evaluation of V.P. 16-213 in malignant lymphoma and melanoma. Cancer Treat. Rep. 62, 801 (1978)

    Google Scholar 

  12. Chakravorty, R. C., Sarker, S. K., Sen, S., Mukerji, B.: Human anticancer effect of podophyllum derivatives (SPG and SPI). Br. J. Cancer 21, 33 (1967)

    Google Scholar 

  13. Cohen, M. H., Broder, L. E., Fossieck, B. E., Ihde, D. C., Minna, J. D.: Phase II clinical trial of weekly administration of V.P. 16-213 in small cell bronchogenic carcinoma. Cancer Treat. Rep. 61, 489 (1977)

    Google Scholar 

  14. Cornman, I., Cornman, M. E.: The action of podophyllin and its fractions on marine eggs. Ann. N.Y. Acad. Sci. 51, 1443 (1951)

    Google Scholar 

  15. Creavan, P. J., Allen, L. M.: E.P.E.G., a new antineoplastic epipodophyllotoxin. Clin. Pharmacol. Ther. 18, 227 (1975)

    Google Scholar 

  16. Creavan, P. J., Newman, S. J., Selawry, O. S., Cohen, M. H., Primack, A.: Phase I clinical trial of weekly administration of 4′-demethylepipodophyllotoxin 9-(4,6-0-ethylidene-β-d-glucopyranoside) NSC 141540: V.P. 16-213. Cancer Chemother. Rep. 58, 901 (1974)

    Google Scholar 

  17. Deysson, G.: Anti-mitotic substances. Int. Rev. Cytol. 24, 99 (1968)

    Google Scholar 

  18. Dombernowsky, P., Nissen, N. I.: Schedule dependency of the anti-leukaemic activity of the podophyllotoxin derivative V.P. 16-213 (NSC 141540) in L 1210 leukaemia. Acta. Path. Microbiol. Scand. [A] 81, 715 (1973)

    Google Scholar 

  19. Dombernowsky, P., Nissen, N. I.: Combination chemotherapy with 4′-demethylepipodophyllotoxin 9-(4,6-0-ethylidene-β-d-glucopyranoside) V.P. 16-213 (NSC 141540) in L 1210 leukaemia. Eur. J. Cancer 12, 181 (1976)

    Google Scholar 

  20. Douglas, H. O., MacIntyre, J. M., Evans, J. T., Kaufman, J., Carbone, P.P.: Methyl C.C.N.U. (MECCNU) plus B-2′-deoxythioguanosine (BTG) vs V.P. 16-213 or diglycoaldehyde (DGA) in advanced previously treated colorectal adenocarcinoma: A Phase II study of the E.C.O.G. Proc. Am. Assoc. Cancer Res. 18, 313 (1977)

    Google Scholar 

  21. Drewinko, B., Barlogie, B.: Survival and cycle progression delay of human lymphoma cells in vitro exposed to V.P. 16-213. Cancer Treat. Rep. 60, 1295 (1976)

    Google Scholar 

  22. Eagan, R. T., Ahmann, D. L., Hahn, R. G., O'Connell, M. J.: Pilot study to determine an intermittent dose schedule for V.P. 16-213. Proc. Am. Assoc. Cancer Res. 16, 55 (1975)

    Google Scholar 

  23. Eagan, R. T., Carr, D. T., Frytak, S., Rubin, J., Lee, R. E.: V.P. 16-213 versus polychemotherapy in patients with advanced small cell lung cancer. Cancer Treat. Rep. 60, 949 (1976)

    Google Scholar 

  24. Eagan, R. T., Ingle, J. N., Creagan, E. T., Frytak, S., Kvois, L. K., Rubin, J., McMahon, R. T.: V.P. 16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung. Cancer Treat. Rep. 62, 843 (1978)

    Google Scholar 

  25. Edmonson, J. H., Deiker, D. G., Malkasian, G. D., Webb, M. J., Jorgensen, E. O.: Phase II evaluation of V.P. 16-213 (NSC 141540) in patients with advanced ovarian carcinoma resistant to alkylating agents. Gynecol. Oncol. 6, 7 (1978)

    Google Scholar 

  26. EORTC Clinical Screening Group: Epipodophyllotoxin V.P. 16-213 in treatment of acute leukaemias, haematosarcomas, and solid tumours. Br. Med. J. 1973, III, 199

    Google Scholar 

  27. Falkson, G., Snyman, H. J.: Experience with chemotherapy of cancer at the University of Pretoria. Acta Union Int. Con. Cancrum 20, 439 (1964)

    Google Scholar 

  28. Falkson, G., Van Dyk, J. J., Van Eden, E. B., Van der Merwe, A. M., Van der Bergh, J. A., Falkson, H. C.: A clinical trial of the oral form of 4′-dmethylepipodophyllotoxin-β-d-ethydine glucoside (NSC 141540) V.P. 16-213. Cancer 35, 1141 (1975)

    Google Scholar 

  29. Freed, J. J., Lebowitz, M. M.: The association of a class of saltatory movements with microtubules in cultured cells. J. Cell Biol. 45, 334 (1970)

    Google Scholar 

  30. Gehan, E. A.: The determination of the number of patients required in a preliminary study and follow up trial of a new chemotherapeutic agent. J. Chronic Dis. 13, 346 (1961)

    Google Scholar 

  31. Grioder, A., Maurer, R., Stähelin, H.: Effect of an epipodophyllotoxin derivative (V.P. 16-213) on macromolecular synthesis and mitosis in mastocytoma cells in vitro. Cancer Res. 34, 1788 (1974)

    Google Scholar 

  32. Grieder, A., Maurer, R., Stähelin, H.: Comparative study of the early effects of epipodophyllotoxin derivatives and other cytostatic agents on mastocytoma cultures. Cancer Res. 37, 2998 (1977)

    Google Scholar 

  33. Hansen, M., Hirsch, F., Dombernowsky, P., Hansen, H. H.: Treatment of small cell anaplastic carcinoma of the lung with the oral solution of V.P. 16-213 (NSC 141540) 4′-demethylepipodophyllotoxin 9-(v,6-0-ethylidene-β-d-glucopyranoside). Cancer 40, 633 (1977)

    Google Scholar 

  34. Huang, C. C., Hou, Y., Wang, J. J.: Effects of a new antitumour agent, epipodophyllotoxin, on growth and chromosomes in human haemopoietic cell lines. Cancer Res. 33, 3123 (1973)

    Google Scholar 

  35. Jungi, W. F., Senn, H. J.: Clinical study of the new podophyllotoxin derivative 4′-demethylepipodophyllotoxin 9-(4,6-0-ethylidene-β-d-glucopyranoside) (NSC 141540: V.P. 16-213) in solid tumours in man. Cancer Chemother. Rep. 59, 737 (1975)

    Google Scholar 

  36. Kaplan, I. W.: Condyloma acuminata: New Orleans Med. Surg. J. 94, 388 (1942)

    Google Scholar 

  37. Kelleher, J. K.: Tubulin binding affinities of podophyllotoxin and colchicine analogues. Mol. Pharmacol. 13, 232 (1977)

    Google Scholar 

  38. Keller-Juslen, C., Kuhn, M., Von Wartburg, A., Stähelin, H.: Synthesis and antimitotic activity of glycosidic lignan derivatives related to podophyllotoxin. J. Med. Chem. 14, 936 (1971)

    Google Scholar 

  39. Kelly, M. G., Hartwell, J. L.: Biological effects and chemical composition of podophyllin. J. Natl. Cancer. Inst., 14, 967 (1954)

    Google Scholar 

  40. Krishan, A., Paika, K., Frei, E., III: Cytofluorometric studies on the action of podophyllotoxin and epipodophyllotoxins (V.M. 26, V.P. 16-213) on the cell cycle traverse of human lymphoblasts. J. Cell Biol. 66, 521 (1975)

    Google Scholar 

  41. Livingston, R. B.: Treatment of small cell carcinoma. Evolution and future directions. Semin. Oncol. 5, 299 (1978)

    Google Scholar 

  42. Loike, J. D., Horwitz, S. B.: Effects of podophyllotoxin and V.P. 16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cells. Biochemistry 15, 5435 (1976)

    Google Scholar 

  43. Loike, J. D., Horwitz, S. B.: Effects of V.P. 16-213 on the intracellular degradation of DNA in the HeLa cells. Biochemistry 15, 5443 (1976)

    Google Scholar 

  44. Loike, J. D., Brewer, C. F., Sternlicht, H., Gensler, W. J., Horwit, S. B.: Structure — activity study of the inhibition of microtubule assembly in vitro by podophyllotoxin and its congeners. Cancer Res. 38, 2688 (1978)

    Google Scholar 

  45. Makrides, E. B., Banerjee, S., Handler, L., Margulis, L.: Podophyllotoxin, colcemid and cold temperature interfere with cilia regeneration. J. Protozool. 17, 548 (1970)

    Google Scholar 

  46. Mathé, G., Schwarzenberg, L., Pouillart, P., Oldham, R., Weiner, R., Jasmin, C., Rosenfield, C., Hayat, M., Misset, J. L., Musset, M., Schneider, M., Amiel, J. L., Vassal, F. de: Two epipodophyllotoxin derivatives V.M. 26 and V.P. 16-213 in the treatment of leukaemias, haematosarcomas, and lymphomas. Cancer 34, 985 (1974)

    Google Scholar 

  47. Misra, N. C., Roberts, D.: Inhibition by 4′-demethylepipodophyllotoxin 9-(4,6-0-2-thenylidene-β-d-glucopyranoside) of human lymphoblast culture in G2 phase of the cell cycle. Cancer Res. 35, 99 (1975)

    Google Scholar 

  48. Mizel, S. B., Wilson, L.: Nucleoside transport in mammalian cells. Inhibition by colchicine. Biochemistry 11, 2573 (1972)

    Google Scholar 

  49. Nissen, N. I., Larsen, V., Pedersen, H., Thomsen, K.: Phase I clinical trial of a new antitumour agent: 4′-Demethylepipodophyllotoxin 9-(4,6-0-ethylidene-β-d-glucopyranoside), NSC 141540: V.P. 16-213. Cancer Chemother. Rep. 56, 769 (1972)

    Google Scholar 

  50. Nissen, N. I., Hansen, H. H., Pedersen, H., Stryer, I., Dombernowsky, P., Hessellund, M.: Clinical trial of the oral form of a new podophyllotoxin derivative, V.P. 16-213 (NSC 141540) in patients with advanced neoplastic disease. Cancer Chemother. Rep. 59, 1627 (1975)

    Google Scholar 

  51. Nissen, N. I., Dombernowsky, P., Hansen, H. H., Larsen, V.: Phase I clinical trial of an oral solution of V.P. 16-213. Cancer Treat. Rep. 60, 943 (1976)

    Google Scholar 

  52. Nuesch, E.: V.P. 16-213/Bioavailability von Lösung und Kapseln. Interne Mitteilung. Basle: Sandoz Ltd. 1974

    Google Scholar 

  53. Paulson, J. C., McClure, W. O.: Microtubules and axioplasmic transport. J. Cell Biol. 67, 461 (1977)

    Google Scholar 

  54. Rivera, G., Avery, T., Roberts, de W.: Response of L 1210 to combination of cytosine arabinoside and V.M. 26 or V.P. 16-213. Eur. J. Cancer 11, 639 (1975)

    Google Scholar 

  55. Rozencweig, M., Von Hoff, D. D., Henney, J. E., Muggia, F. M.: V. M. 26 and V.P. 16-213. A comparative analysis. Cancer 40, 334 (1977)

    Google Scholar 

  56. Schecter, J. P., Jones, S. E.: Myocardial infarction in a 27-year-old woman: possible complication of treatment with V.P. 16-213 (NSC 141540) mediastinal irradiation or both. (Letter.). Cancer Treat. Rep. 59, 887 (1975)

    Google Scholar 

  57. Smith, I. E., Clink, H. MacD. Gerken, M. E., McElwain, T. J.: V.P. 16-213 in acute myelogenous leukaemia. Postgrad. Med. J. 52, 66 (1976)

    Google Scholar 

  58. Stähelin, H.: 4′-Demethyl-epipodophyllotoxin thenylidene glucoside (V.M.26), a podophyllum compound with a new mechanism of action. Eur. J. Cancer 6, 303 (1970)

    Google Scholar 

  59. Stähelin, H.: Activity of a new glycosidic lignan derivative (V.P. 16-213) related to podophyllotoxin in experimental tumours. Eur. J. Cancer 9, 215 (1973)

    Google Scholar 

  60. Sullivan, B. J., Wechsler, H. I.: The cytological effects of podophyllin. Science 105, 433 (1947)

    Google Scholar 

  61. Tucker, R. D., Ferguson, A., Van Wyk, C., Sealy, R., Hewitson, R., Levin, W., Rad, R. F.: Chemotherapy of small cell carcinoma of the lung with V.P. 16-213. Cancer 41, 1710 (1978)

    Google Scholar 

  62. Vaitkevicius, V. K., Reed, M. L.: Clinical studies with podophyllum compound SPI-77 (NSC-72274) and SPD-827 (NSC 42076). Cancer Chemother. Rep. 50, 565 (1966)

    Google Scholar 

  63. Vietti, T. J., Valeriote, F. A., Kalish, R., Coulter, B.: Kinetics of cytotoxicity of V.M. 26 and V.P. 16-213 on leukaemia L 1210 and haematopoietic stem cells. Cancer Treat. Rep. 62, 1313 (1978)

    Google Scholar 

  64. Wang, J. J., Chervinsky, D. S.: Effect of a podophyllotoxin derivative (V.P. 16-213) on nucleic acid and protein biosynthesis in L 1210 leukaemic cells. Proc. Am. Assoc. Cancer Res. 14, 100 (1973)

    Google Scholar 

  65. Wilson, L., Bryan, J.: Biochemical and pharmacological properties of microtubules. Adv. Cell. Mol. Biol. 3, 21 (1974)

    Google Scholar 

  66. Wilson, L., Friedkin, M.: The biochemical events of mitosis. II. The in vivo and in vitro binding of colchicine in grasshopper embryos: its possible relation to inhibition of mitosis. Biochemistry 6, 3126 (1967)

    Google Scholar 

  67. Wilson, L., Bamburg, J. R., Mizel, S. B., Grisham, I. M., Crewell, K. M.: Interaction of drugs with microtubule proteins. Fed. Proc. 33, 158 (1974)

    Google Scholar 

  68. Young, C. W., Ihde, D. C., von Stubbe, W.: Preliminary clinical trial of 4′-demethylepipodophyllotoxin-β-d-ethylidene-glucoside, V.P. 16-213. Proc. Am. Assoc. Cancer Res. 14, 60 (1973)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. CRC Medical Oncology Unit, Level F, Centre Block, Southampton General Hospital, Southampton, England

    A. M. Arnold

Authors
  1. A. M. Arnold
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arnold, A.M. Podophyllotoxin derivative VP 16-213. Cancer Chemother. Pharmacol. 3, 71–80 (1979). https://doi.org/10.1007/BF00254976

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00254976

Keywords

Search

Navigation